Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study

Table 2

MMSC donor and graft characteristics.

Donors	Values
Sex of donors, M/F	19/18
Median age, years (range)	34 (13–68)
MMSCs
Culture passage at MMSCs harvest	0–3
Immunophenotype
CD105 (Endoglin)	98,6 ± 0,2%
CD73 (SH3, SH4)	98,1 ± 0,5%
CD90 (Thy-1)	98 ± 0,5%
CD59	98,8 ± 0,1%
Fibroblast Surface Protein (FSP)	97 ± 0,4%
CD31 (PECAM-1)	2,5 ± 0,7%
HLA-DR	3,7 ± 0,7%
CD34	0,00%
CD45	4,5 ± 0,8%
CD14	2,0 ± 0,6%
Proportion of viable cells, %	95.3±1.3%
Median MMSCs cell dose (×10^6/kg, range)	1.1 (0.9–1.3)
Relative expression level of several genes in MMSCs on passage 2
IL-6	2.57±0.98
Ptges	10.07±3.16
CSF1	2.04±0.39
IDO1	0.36±0.132
IL-10	2.73±0.6
CFH	1.98±0.36